N-Methyl-2-Pyridone Compounds for Selective BDII Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing BET protein inhibitors often lack selectivity for BDII over BDI, leading to unwanted side effects and a lower therapeutic index, and there is a need for BET protein inhibitors that are stable, soluble, and have low skin and liver toxicity.
Innovation Solution
Development of novel N-methyl-2-pyridone compounds and compositions that selectively inhibit BDII, are highly soluble, stable under various pH conditions, and exhibit rapid liver clearance, reducing the risk of side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pan-BET inhibitors are used to inhibit all four BET BRDs, then broad anti-inflammatory and anti-cancer activity is achieved, but therapeutic index is reduced and side effects increase
Solution Approach 1:
The invention segments the BET protein family inhibition into selective targeting of BDII domain versus BDI domain. By designing compounds that selectively inhibit BDII-containing BET proteins (BRD2, BRD3, BRD4) while sparing BDI, the patent achieves differential inhibition that improves therapeutic index and reduces side effects associated with pan-BET inhibition.
Solution Approach 2:
The patent applies local quality by introducing specific structural features (N-methyl-2-pyridone moiety with particular substitution patterns) that confer selective binding affinity for BDII over BDI. This localized structural modification creates compounds with differentiated inhibition profiles across BET protein family members.
2Adaptability or versatility
If BET protein inhibitors are developed for broad inhibition, then efficacy against multiple diseases is improved, but selectivity for specific domains is reduced
Solution Approach 1:
The patent employs asymmetry in molecular design by creating compounds with N-methyl-2-pyridone core structures that exhibit asymmetric binding preferences for BDII domain. This asymmetric molecular architecture enables selective interaction with BDII-containing BET proteins while maintaining broad applicability across multiple disease indications.
3Reliability
If compounds are designed for high potency inhibition, then nanomolar activity is achieved, but solubility and stability may be compromised
Solution Approach 1:
The patent applies parameter changes by systematically varying substituents on the N-methyl-2-pyridone core (including groups at positions 3, 4, 5, 6) to optimize the balance between potency and physicochemical properties. By adjusting parameters such as substituent type, position, and stereochemistry, the invention achieves nanomolar potency while maintaining adequate solubility and metabolic stability.
Data Source
AI summary
The present invention concerns compounds comprising N-methyl-2-pyridone, and pharmaceutically-acceptable salts and compositions of such compounds. Such compounds are useful in anti-inflammatory and anti-cancer therapies. Therefore, the present invention also concerns such compounds for use as medicaments, particularly for the treatment of inflammatory diseases and oncology.